查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190650

药物洗脱球囊市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Drug Eluting Balloon Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，药物洗脱球囊市场预计将以 18% 左右的复合年增长率增长。

COVID-19 对市场的增长产生了重大影响。 由于高感染率和隔离限制，COVID-19 大流行对外科手术产生了不利影响。 由于医院和诊断中心的入院人数减少，心血管疾病患者的诊断和治疗延误也影响了市场。 这种诊断和治疗的延误导致对药物洗脱球囊的需求略有下降，影响了市场增长。 例如，2022 年 3 月在 NCBI 发表的一项研究发现，成人心臟手术量减少了 52.7%，选择性病例减少了 65.5%，表明 COVID-19 对心臟手术的负面影响。 然而，2021 年 4 月发表的另一项 NCBI 研究称，COVID-19 可以通过 ACE2 增加动脉粥样硬化的发展，ACE2 也是 SARS-CoV-2 病毒的受体。 因此，COVID-19 对人体的长期影响可能会增加动脉硬化等心脏病的患病率，从而增加对药物洗脱球囊的需求，并为市场增长做出贡献。期待您的贡献。

此外，全球冠状动脉疾病和外周动脉疾病发病率的增加也有望推动市场增长。 政府和私人组织加大研发力度，以及为提高人们对心脏病的认识所做的不懈努力，也在推动市场的增长。

根据澳大利亚健康与福利研究所的数据，到 2022 年 5 月，在 1180 万住院患者中，7.0% 在重症监护室，3.8% 因心血管疾病住院。 根据美国心臟协会 2021 年报告，外周动脉疾病 (PAD) 影响全球 2 亿多人，并与高死亡率和发病率相关。 此外，易患心血管疾病的老龄化人口增加和医疗成本上升预计将推动市场增长。 例如，爱思唯尔 (Elsevier) 于 2021 年 12 月发布的调查结果显示，在 45 岁及以上的人群中，自我报告的已确诊心血管疾病 (CVD) 的总体患病率为 29.4%。 随着年龄的增长，患病率从 45-54 岁的 22% 增加到 70 岁及以上的 38%，这表明老年人患心血管疾病的风险增加。 这些心血管疾病的流行预计将推动对药物洗脱球囊的需求，因为药物洗脱球囊用于治疗多种心血管疾病，从而帮助患病患者康復。

然而，药物洗脱球囊的开发和商业化成本高昂，加上严格的监管程序，阻碍了市场增长。

药物洗脱球囊市场趋势

周边药物洗脱球囊有望在预测期内实现健康成长

药物洗脱球囊在外周动脉疾病的治疗中发挥着重要作用。 外周动脉疾病患病率上升和老年人口增加预计将推动该领域的增长。

根据美国心臟协会 2021 年报告，外周动脉疾病 (PAD) 影响着全世界 2 亿多人，并且与高死亡率和发病率有关。 随着世界人口老龄化，PAD 可能变得越来越普遍。 统计数据显示，PAD 正在以更快的速度增长，这最终推动了外周药物洗脱球囊的细分市场。 根据美国心臟协会 2021 年 8 月发表的另一项科学研究，下肢 PAD 影响全球超过 2.3 亿人，并与冠心病和中风等多种不良临床结果相关。 ， ETC。）。 由于 PAD 发病率的增加，预计在预测期内外周药物洗脱球囊的使用将会增加。

由于药物洗脱球囊在外周动脉疾病治疗中的使用增加、扩大适应症的研发增加以及上市，预计外周药物洗脱球囊部分将占据很大份额外周动脉部分的新产品。

预期的产品发布以及创新涂层和气球技术的开发预计将在预测期内推动该细分市场的增长。

预计在预测期内北美将占据很大的市场份额

在北美，久坐不动的生活方式加上缺乏运动、饮食不当、焦虑和压力导致糖尿病和肥胖等慢性病以及冠状动脉疾病、中风和心房颤动等多种心血管疾病。很大程度上是由于患病率上升

Cedars Sinai 于 2022 年 1 月更新的数据显示，冠状动脉旁路移植手术 (CABG)，也称为冠状动脉搭桥或搭桥手术，是最常见的心臟手术类型。 在美国，每年有超过 300,000 人成功地进行搭桥手术。 此类与心血管疾病相关的各种外科手术的负担预计将推动对药物洗脱球囊的需求，为该地区的市场增长创造有利可图的机会。

此外，根据美国疾病控制与预防中心 (CDC) 于 2022 年 7 月更新的数据，冠心病是美国 20 岁及以上成年人中最常见的心脏病类型。约有 2010 万人已被证明患有这种疾病。 根据CDC数据，每40秒就有一人心脏病发作，美国每年有近80.5万人心脏病发作。 由于心血管疾病的高负担，需要使用药物洗脱球囊。

特别是北美新兴国家，心脏病患者多，医疗费用增加，市场有望增长。

药物洗脱球囊市场竞争分析

药物洗脱球囊市场整合度适中，竞争激烈。 公司正专注于气球技术的创新和扩大产品适应症以增加市场份额。 市场上的主要市场参与者包括 Medtronic PLC、Boston Scientific Corporation、Becton、Dickson and Company、Terumo Corporation、Koninklijke Philips NV 等。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 外周动脉疾病和冠状动脉疾病的患病率增加
    • 导致心血管疾病的老年人口增加
  • 市场製约因素
    • 药物洗脱球囊的开发和商业化成本高昂
    • 副作用和产品召回
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品分类
    • 用于冠状动脉的药物洗脱球囊
    • 外周药物洗脱球囊
    • 其他产品（肾臟/泌尿科）
  • 按技术
    • 免费包
    • 反包
    • Endura 外套
    • 其他技术
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Medtronic PLC
    • Boston Scientific Corporation
    • Becton, Dickson and Company
    • Terumo Corporation
    • Koninklijke Philips NV
    • Cook Group Incorporated
    • Biotronik
    • B. Braun Melsungen AG
    • SurModics Inc.

第7章 市场机会今后动向

简介目录
Product Code: 67876

The drug-eluting balloon market is expected to register an approximate CAGR of 18% during the forecast period.

COVID-19 had a significant impact on the growth of the market. The COVID-19 pandemic has negatively affected surgical procedures due to the high rate of infection and lockdown restrictions. A delay in diagnosis and treatments was also observed in patients with cardiovascular diseases as a result of a reduction of footfall in hospitals and diagnostic centers, which impacted the market studied as well. Such delay in diagnosis and treatment led to a slight decrease in the demand for drug-eluting balloons, thereby affecting the growth of the market. For instance, according to a research study published in NCBI in March 2022, there was a 52.7% reduction in the volume of adult cardiac surgeries and a 65.5% reduction in elective cases, which indicated the negative impact of COVID-19 on cardiac surgical procedures. However, another NCBI research study published in April 2021 stated that COVID-19 could increase the development of atherosclerosis due to ACE2, which is also a receptor for the SARS-CoV-2 virus. Thus, the long-term effect of COVID-19 on the human body may increase the prevalence of atherosclerosis and other cardiac diseases, which is expected to increase the demand for drug-eluting balloons, thereby by contributing to the growth of the market.

The increasing incidence of coronary and peripheral artery diseases around the world is expected to boost the market's growth. In addition, increasing research and development supported by government and private institutions and continuous initiatives about awareness regarding heart diseases are fuelling the market growth.

According to the Australian Institute of Health and Welfare, in May 2022, out of 11.8 million admissions, 7.0% of hospitalizations involved a stay in the intensive care unit, and 3.8% of hospitalizations involved cardiovascular diseases. According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases, and growing healthcare spending are projected to bolster market growth. For instance, according to the research study published in December 2021, by Elsevier, for older people aged 45 and above, the overall self-reported prevalence of diagnosed cardiovascular diseases (CVDs) was 29.4%. The prevalence rate increased with age, from 22% in the 45-54 age group to 38% in the 70+ age group, showing that the senior population is at high risk of having CVDs. Such prevalence of various cardiovascular conditions is expected to drive the demand for drug-eluting balloons as they are used to treat various cardiovascular conditions, thereby helping in the recovery of affected patients.

However, the high cost of development and commercialization of drug-eluting balloons, coupled with stringent regulatory procedures, are hampering the market growth.

Drug Eluting Balloon Market Trends

Peripheral Drug-eluting Balloons are Expected to Grow at a Healthy Rate Over the Forecast Period

Drug-eluting balloons play an important role in the treatment of peripheral artery diseases. The growing prevalence of peripheral artery diseases, coupled with the increasing geriatric population, is expected to boost segment growth.

According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. With the aging global population, PAD may likely become increasingly common. Statistics show that PADs are increasing at a faster pace, which is ultimately driving the segment for peripheral drug-eluting balloons. Another scientific study published by the American Heart Association in August 2021 stated that lower extremity PAD affects more than 230 million people worldwide and is linked to an elevated risk of several unfavorable clinical outcomes (including cardiovascular diseases like coronary heart disease and stroke and limb outcomes, like amputee status). The increased incidence of PAD is expected to boost the use of peripheral drug-eluting balloons over the forecast period.

The segment for peripheral drug-eluting balloons is expected to have a significant share owing to the increased usage of drug-eluting balloons in the treatment of peripheral artery diseases and growing R&D in expanding the indications, and new product launches in the peripheral artery segment.

The anticipated product launches, coupled with the development of innovative coating and balloon technologies, are expected to boost the segment's growth over the forecast period.

North America is Expected to Have Significant Market Share Over the Forecast Period

The major factors attributing to the growth are a sedentary lifestyle lacking physical activity, lack of proper diet, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases like coronary artery disease, strokes, and atrial fibrillation.

The data updated by Cedars-Sinai in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass, or bypass surgery, is the most common type of heart surgery. More than 300,000 people have successful bypass surgeries in United States each year. Such a burden of various cardiovascular disease-related surgical procedures is expected to drive the demand for drug-eluting balloons and provide lucrative opportunities for the growth of the market in this region.

In addition, the Centers for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in United States. Per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of drug-eluting balloons.

The presence of a large pool of people with heart diseases and growing healthcare spending, especially in emerging countries of North America, are expected to boost the market growth.

Drug Eluting Balloon Market Competitive Analysis

The drug-eluting balloon market is moderately consolidated and competitive. Companies are focusing on innovating balloon technologies and expanding product indications to increase their market share. The key market players operating in the market include Medtronic PLC, Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, and Koninklijke Philips NV, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Peripheral and Coronary Artery Diseases
    • 4.2.2 Rising Geriatric Population Leading to Cardiovascular Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Development and Commercialization of Drug-eluting Balloons
    • 4.3.2 Adverse Effects and Product Recalls
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Coronary Drug-eluting Balloon
    • 5.1.2 Peripheral Drug-eluting Balloon
    • 5.1.3 Other Products (Renal/Urology)
  • 5.2 By Technology
    • 5.2.1 FreePac
    • 5.2.2 TransPac
    • 5.2.3 EnduraCoat
    • 5.2.4 Other Technologies
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic PLC
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Becton, Dickson and Company
    • 6.1.4 Terumo Corporation
    • 6.1.5 Koninklijke Philips NV
    • 6.1.6 Cook Group Incorporated
    • 6.1.7 Biotronik
    • 6.1.8 B. Braun Melsungen AG
    • 6.1.9 SurModics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS